
- Pharmaceutical Executive-06-01-2008
- Volume 0
- Issue 0
Mike Boken, Shire
S
Mike Boken
Senior Director of Marketing, Vyvanse, Shire
BIG DEAL: Launching Prevnar, the first blockbuster vaccine
SUCCESS IS: 1 million Vyvanse scripts written 10 months after launch
You have to find a way to make your drug stand out from everybody else," says Mike Boken. He speaks from experience: Standing 7 feet tall, he never gets lost in the crowd.
Mike Boken
There's another truism that Boken lives by. As one of nine brothers and sisters, his mother expected chores to be done right—or else. "What I remember is that if you do it right the first time, you'll be in a better place."
Boken has applied that philosophy to promotion of Adderall XR and its ADHD follow up Vyvanse by developing smart adherence programs that keep patients on drug the first time around. It turns out that what's best for the patient is also best for the company: "We've seen the best ROIs coming from those retention programs."
Articles in this issue
over 17 years ago
Mary Szela, Abbottover 17 years ago
Mightier Than the Swordover 17 years ago
Keeshia Muhammad, Teva Specialty Pharmaceuticalsover 17 years ago
Eric Floyd, Cephalonover 17 years ago
Nancy Phelan, Wyethover 17 years ago
Tightening the Chainover 17 years ago
Kurt Graves, Vertexover 17 years ago
Wendy Niebler, Shireover 17 years ago
Perfectly ImperfectNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.